Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer (clinicaltrials.gov) - Apr 3, 2026 - P1 | N=48 | Recruiting | Sponsor: Washington University School of Medicine | Not yet recruiting ➔ Recruiting
Enrollment open • Biliary Cancer • Biliary Tract Cancer • Cholangiocarcinoma • Gallbladder Cancer • Oncology • Solid Tumor
|